IBDEI0Z6 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17471,0)
 ;;=238.3^^111^1088^2
 ;;^UTILITY(U,$J,358.3,17471,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17471,1,1,0)
 ;;=1^238.3
 ;;^UTILITY(U,$J,358.3,17471,1,8,0)
 ;;=8^Breast
 ;;^UTILITY(U,$J,358.3,17471,2)
 ;;=^81956
 ;;^UTILITY(U,$J,358.3,17472,0)
 ;;=238.4^^111^1088^15
 ;;^UTILITY(U,$J,358.3,17472,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17472,1,1,0)
 ;;=1^238.4
 ;;^UTILITY(U,$J,358.3,17472,1,8,0)
 ;;=8^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,17472,2)
 ;;=^304816
 ;;^UTILITY(U,$J,358.3,17473,0)
 ;;=238.5^^111^1088^6
 ;;^UTILITY(U,$J,358.3,17473,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17473,1,1,0)
 ;;=1^238.5
 ;;^UTILITY(U,$J,358.3,17473,1,8,0)
 ;;=8^Histiocytic and Mast Cells
 ;;^UTILITY(U,$J,358.3,17473,2)
 ;;=^267778
 ;;^UTILITY(U,$J,358.3,17474,0)
 ;;=238.6^^111^1088^14
 ;;^UTILITY(U,$J,358.3,17474,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17474,1,1,0)
 ;;=1^238.6
 ;;^UTILITY(U,$J,358.3,17474,1,8,0)
 ;;=8^Plasma Cells
 ;;^UTILITY(U,$J,358.3,17474,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,17475,0)
 ;;=238.71^^111^1088^4
 ;;^UTILITY(U,$J,358.3,17475,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17475,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,17475,1,8,0)
 ;;=8^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,17475,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,17476,0)
 ;;=238.72^^111^1088^7
 ;;^UTILITY(U,$J,358.3,17476,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17476,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,17476,1,8,0)
 ;;=8^Low Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,17476,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,17477,0)
 ;;=238.73^^111^1088^5
 ;;^UTILITY(U,$J,358.3,17477,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17477,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,17477,1,8,0)
 ;;=8^High Grade Myelody Synd Lesion
 ;;^UTILITY(U,$J,358.3,17477,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,17478,0)
 ;;=238.74^^111^1088^9
 ;;^UTILITY(U,$J,358.3,17478,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17478,1,1,0)
 ;;=1^238.74
 ;;^UTILITY(U,$J,358.3,17478,1,8,0)
 ;;=8^Myelody Synd w/ 5q Deletion
 ;;^UTILITY(U,$J,358.3,17478,2)
 ;;=^334030
 ;;^UTILITY(U,$J,358.3,17479,0)
 ;;=238.75^^111^1088^10
 ;;^UTILITY(U,$J,358.3,17479,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17479,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,17479,1,8,0)
 ;;=8^Myelodysplastic Syndrome
 ;;^UTILITY(U,$J,358.3,17479,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,17480,0)
 ;;=238.76^^111^1088^11
 ;;^UTILITY(U,$J,358.3,17480,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17480,1,1,0)
 ;;=1^238.76
 ;;^UTILITY(U,$J,358.3,17480,1,8,0)
 ;;=8^Myelofibrosis w/Myeloid Metaplasia
 ;;^UTILITY(U,$J,358.3,17480,2)
 ;;=^334032
 ;;^UTILITY(U,$J,358.3,17481,0)
 ;;=238.77^^111^1088^16
 ;;^UTILITY(U,$J,358.3,17481,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17481,1,1,0)
 ;;=1^238.77
 ;;^UTILITY(U,$J,358.3,17481,1,8,0)
 ;;=8^Post Transp Lymphoprolif d/o PTLD
 ;;^UTILITY(U,$J,358.3,17481,2)
 ;;=^336526
 ;;^UTILITY(U,$J,358.3,17482,0)
 ;;=238.79^^111^1088^12
 ;;^UTILITY(U,$J,358.3,17482,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17482,1,1,0)
 ;;=1^238.79
 ;;^UTILITY(U,$J,358.3,17482,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue
 ;;^UTILITY(U,$J,358.3,17482,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,17483,0)
 ;;=238.8^^111^1088^13
 ;;^UTILITY(U,$J,358.3,17483,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17483,1,1,0)
 ;;=1^238.8
 ;;^UTILITY(U,$J,358.3,17483,1,8,0)
 ;;=8^Oth Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,17483,2)
 ;;=^267779
 ;;^UTILITY(U,$J,358.3,17484,0)
 ;;=238.9^^111^1088^8
 ;;^UTILITY(U,$J,358.3,17484,1,0)
 ;;=^358.31IA^8^2
